Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Credit NIAID-RML
Highlighted Sections
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Prevention of SARS-CoV-2
The Panel now recommends against the use of tixagevimab plus cilgavimab (Evusheld) as COVID-19 pre-exposure prophylaxis.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
The Panel added information from 2 case series that describe clinical experience with ritonavir-boosted nirmatrelvir in pregnant patients with COVID-19.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Ivermectin
Three large randomized controlled trials have reported that ivermectin did not provide a clinical benefit for patients with mild to moderate COVID-19.
Clinical Spectrum
The information on breakthrough infection, viral or symptom rebound after COVID-19, and prolonged viral shedding has been updated.
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Prevention of SARS-CoV-2
The Panel now recommends against the use of tixagevimab plus cilgavimab (Evusheld) as COVID-19 pre-exposure prophylaxis.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
The Panel added information from 2 case series that describe clinical experience with ritonavir-boosted nirmatrelvir in pregnant patients with COVID-19.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Ivermectin
Three large randomized controlled trials have reported that ivermectin did not provide a clinical benefit for patients with mild to moderate COVID-19.
Clinical Spectrum
The information on breakthrough infection, viral or symptom rebound after COVID-19, and prolonged viral shedding has been updated.
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Prevention of SARS-CoV-2
The Panel now recommends against the use of tixagevimab plus cilgavimab (Evusheld) as COVID-19 pre-exposure prophylaxis.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
The Panel added information from 2 case series that describe clinical experience with ritonavir-boosted nirmatrelvir in pregnant patients with COVID-19.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Ivermectin
Three large randomized controlled trials have reported that ivermectin did not provide a clinical benefit for patients with mild to moderate COVID-19.
Clinical Spectrum
The information on breakthrough infection, viral or symptom rebound after COVID-19, and prolonged viral shedding has been updated.